FDA approves new formulation for filterless administration of Protonix I.V.
FDA approves new formulation for filterless administration of Protonix I.V.
MADISON, N.J., April 12, 2004 -- Wyeth Pharmaceuticals announced
FDA has approved the reformulation of the stomach acid suppressant,
Protonix I.V. (pantoprazole sodium) for Injection. The
reformulation eliminates the need for an in-line filter, a
previously required extra step in an already time-sensitive
procedure to administer the medication to patients requiring
immediate acid suppression.
Protonix is the first proton pump inhibitor (PPI) in the United
States to be offered in both oral and intravenous (I.V.)
formulations. The new formulation will replace the existing
Protonix I.V. formulation, which has been used clinically for seven
years in more than five million patients worldwide.
"Protonix I.V., currently used in over 5,000 hospitals, has established a high standard of care for I.V. PPI therapy," said Joseph Camardo, M.D., Senior Vice President of Global Medical Affairs and Medical Director for Wyeth Pharmaceuticals North America. "Without the need for a filter, the reformulated product is more convenient for hospital pharmacists and nurses to use."
The new formulation has been approved for administration either as a 2-minute or 15-minute infusion. Protonix I.V. received FDA approval in December 2003 for administration as a 2-minute infusion. This alternative infusion approach may reduce drug preparation time and administration costs in hospitals, since the intravenous admixture bag can be replaced with a less expensive syringe for administration.
The FDA first approved Protonix I.V. in March 2001 for the short-term, treatment (7 to 10 days) of patients having gastroesophageal reflux disease (GERD) with a history of erosive esophagitis, as an alternative to oral therapy in patients who are unable to continue taking Protonix Delayed- Release Tablets. Safety and efficacy of Protonix I.V. as an initial treatment of patients having GERD with a history of erosive esophagitis have not been demonstrated.
Protonix I.V. received expedited FDA approval in October 2001 for the treatment of pathological hypersecretory conditions associated with Zollinger- Ellison Syndrome or other neoplastic conditions.
For full Prescribing Information, www.wyeth.com
Source: Wyeth
Pharma Industry News Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec
